Ads
related to: lipidomics cancer drug treatment singapore
Search results
Results From The WOW.Com Content Network
Cancer treatment centres in Singapore are generally located in both public and private hospitals. These units and medical centres specialise in the treatment of cancer . [1] Raffles Hospital; Parkway East Hospital - Parkway Cancer Centre; Gleneagles Hospital - Parkway Cancer Centre [2] Tan Tock Seng Hospital; Singapore General Hospital
Markus R. Wenk is a Swiss biochemist and academic. He is Dean of the College of Health and Life Sciences at Hamad Bin Khalifa University. [1]Wenk's research focuses on the structure and function of membranes, the metabolism of lipids, the advancement of lipidomics, and incorporating precise molecular analysis into medical research for personalized health. [2]
The National University Cancer Institute, Singapore (NCIS) is a national specialty centre and the only public cancer centre in Singapore treating both paediatric and adult cancers in one facility. The NCIS offers a broad spectrum of cancer care and management that ranges from public education, screening and early diagnosis, to treatment, and ...
(Reuters) -AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug conjugates (ADCs), the Anglo ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
Lipidomics is a research field that studies the pathways and networks of cellular lipids in biological systems (i.e., lipidomes) on a large scale. It involves the identification and quantification of the thousands of cellular lipid molecular species and their interactions with other lipids, proteins, and other moieties in vivo.
Inavolisib (codenamed GDC-0077; PIK3CA inhibitor) will be tested as a potential treatment for PIK3CA-mutant breast cancer in a phase II/III trial (NCT04191499). The trial is currently recruiting patients as of March 2022 and will compare inavolisib + palbociclib + fulvestrant with placebo + palbociclib + fulvestrant. Results are expected for ...
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.